NEW YORK (GenomeWeb) – Clinical Genomics said today that it is initiating a therapy monitoring study with investigators at Memorial Sloan Kettering Cancer Center, which will evaluate the ability of the company's Colvera liquid biopsy assay to measure the presence of rectal cancer during and after treatment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.